Citi analyst Joanne Wuensch downgraded Tandem Diabetes (TNDM) to Neutral from Buy with a price target of $24, down from $35. The firm sees increased uncertainty following the company’s 2025 guidance. Quarter end softness in the U.S. attributed to shipping delays and muted seasonality, outside the U.S. disruption as the company’s shifts to direct from distributor sales, and new product timing for weighing on Tandem’s outlook, the analyst tells investors in a research note. Citi reduced estimates post the earnings print and downgraded the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Wells Fargo downgrades Tandem Diabetes on market share loss
- Tandem Diabetes downgraded to Equal Weight from Overweight at Wells Fargo
- Tandem Diabetes downgraded to Market Perform from Outperform at Bernstein
- Tandem Diabetes price target lowered to $53 from $60 at Barclays